Intercytex is the leading developer of regenerative
medicine products. Intercytex uses its fully integrated cell
technology platform to develop living, human cell-based products
that harness the innate ability of human cells to regenerate and
repair the body, at commercially viable scale in attractive
markets.
Intercytex commenced operations in 2000 and currently employs
around 50 staff. In addition to its head office in Cambridge,
UK, it has its own GMP compliant clinical production facility
plus research and development laboratories in Manchester, UK
and a dedicated stem cell research laboratory in Sheffield,
UK. Additional laboratories are located in Boston, US..
Intercytex’ shares trade on the Alternative Investment
Market of the
London Stock Exchange under the ticker symbol ICX.L.
 Corporate fact sheet
|
Contact Us
